PIALAT @PMPIA12

French radiation oncologist, loving life ! GROP, Tarbes Tarbes, France Joined February 2018

Tweets

147
Followers

59
Following

289
Likes

675

Rohit Malde @roxboxfix

5 months ago

Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST tria) ASCO 2026

1 20 39 2K 23

View Details

Pierre Blanchard, MD @PBlanchardMD

5 months ago

Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n

7 85 152 18K 76

View Details

Dr. Nina Niu Sanford @NiuSanford

10 months ago

PLATO ACT5 Ph3 RCT (n=463): 53.2 v 58.8 v 61.6 Gy in T3-4/N+ anal SCC. No early benefit to dose escalation w similar cCR (65-67%) across dose levels. More uniform RT dose is not the answer – need better stratification, bio-driven personalization, RT/systemic integration. #GI26

1 34 80 5K 27

View Details

David Palma, MD, PhD @drdavidpalma

a year ago

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

19 83 310 30K 49

View Details

giuseppe Minniti @gminniti2012

a year ago

Happy to introduce something different from classical curative or palliative radiotherapy: Strategic radiotherapy: a new proof of concept sciencedirect.com/science/articl… @ESTRO_RT @SapienzaRoma

9 40 117 11K 34

View Details

Yakup Ergün @dr_yakupergun

a year ago

The effectiveness of pembrolizumab maintenance w/wo pemetrexed after induction treatment for advanced nsqNSCLC 2333 pts, retrospective 💥The addition of pemetrexed to pembrolizumab maintenance did not show an OS benefit 21.0 (pembro) vs 18.2 mo (dual) lungcancerjournal.info/article/S0169-…

2 31 92 8K 35

View Details

Rohit Malde @roxboxfix

a year ago

First RCT comparing Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma

2 13 28 3K 14

View Details

Piet Ost @piet_ost

a year ago

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1

3 59 152 12K 41

View Details

C. Jillian Tsai, MD, PhD @CJTsaiMDPhD

a year ago

Promising result! Why not consider (lower dose SIB) hypofractionated nodal RT as well with primary SBRT? #ESTRO2025 #lcsm @DrewMoghanaki @PercyLeeMD

Gerry Hanna @gerryhanna

a year ago

What about #SABR / #SBRT to the primary tumour in LA-NSCLC? This study just presented at #ESTRO25 has promising survival with little toxicity rates ➡️ improvement in PFS ➡️ trend toward better OS

2 32 78 10K 35

3 12 26 5K 8

View Details

Gustavo @gusviani

2 years ago

Want to discuss the Sabr-5 further? Check out the full post on RadOnc Insights!👇 open.substack.com/pub/gusviani/p…

1 2 2 305 3

View Details

Shankar Siva @_ShankarSiva

2 years ago

📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc

4 118 226 33K 55

View Details

Luis Moreno Sánchez @drluismorenos

2 years ago

Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group. pubmed.ncbi.nlm.nih.gov/39418694/

1 32 80 8K 46

View Details

Journal of Clinical Oncology @JCO_ASCO

2 years ago

Thoracic Radiotherapy Improves the Survival in Pts With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell #LungCancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial brnw.ch/21wNZM6 #NSCLC

1 8 19 4K 9

View Details

Amar Kishan @AmarUKishan

2 years ago

RAIDER trial out in @EUplatinum europeanurology.com/article/S0302-… Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy

2 37 76 8K 17

View Details

NEJM @NEJM

2 years ago

@myESMO Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (ADRIATIC) 📄 Full article: nej.md/4d0eZ5m

3 4 11 2K 3

View Details

Niema Razavian, MD @RadOncDoc_Niema

2 years ago

Its here! After 2⃣ years under review, our manuscript on unilateral neck treatment (🔪 and/or ☢️) in pts with tonsil cancer is out now in ORL. In this group of T1-2N0-2b pts, there were 0⃣ contralateral neck failures after unilat tx 🔗: tinyurl.com/3jnc2anv #radonc #hncsm

9 22 88 6K 15

View Details

Aisling Barry @aislingbarryro

2 years ago

📣Single fraction palliative RT for painful liver cancer vs best supportive care #rct ➡️4/10 pain @ base ➡️liver Mets/#HCC ➡️ 67% vs 22% SS pain improv @1m with RT 💪 ➡️no sig inc side effects ➡️3m survival 51% vs 33% ns @ldawsonmd @RadMedPM @CanResUCC thelancet.com/journals/lanon…

1 18 49 5K 7

View Details

Gerry Hanna @gerryhanna

2 years ago

Secondaryanalysis of RTOG0617 in @JAMAOnc ➡️IMRT🟰2x reduction in severe pneumonitis and < cardiac exposure than 3D-CRT ➡️🫁volume receiving low-dose (lung V5) did not affect survival or severe adverse events ➡️❤️volume receiving 40Gy (<20%) assoc with⬆️OS jamanetwork.com/journals/jamao…

0 21 46 6K 12

View Details

Vincent Alcazer @AlcazerVincent

3 years ago

Our article is finally out in @LancetDigitalH thelancet.com/journals/landi… --> Diagnosis of acute leukaemia subtypes (APL/AML/ALL) based on routine laboratory parameters using machine learning The model is broadly available in an online-app: alcazerv.shinyapps.io/AIPAL/

4 16 44 5K 20

View Details

Matthias Guckenberger @Mat_Guc

3 years ago

Brain mets: optimal sequencing of local Tx (LT) & CNS active systemic Tx remains unkown - retrospective study of 121 pts with EGFR mut NSCLC - 45 & 76 pts treated with upfront LT vs osimertinib alone 👉 upfront LT improved OS (HR 0.37), CNS-PFS (HR 0.36) lungcancerjournal.info/article/S0169-…